Prof. Dr. Hristo Svilenov
Academic Career and Research Areas
Prof. Svilenov (*1988) conducts research in the field of biopharmaceutical technology. The main focus is on recombinant therapeutic proteins produced in mammalian cell culture. By using orthogonal analytical methods, the group provides mechanistic insights into novel proteins and bioprocesses that support the development of new medicines.
Prof. Svilenov studied Pharmacy at the Medical University in Sofia. He defended his PhD thesis in Pharmaceutical Technology at the Ludwig Maximilian University of Munich (2019). After a post-doctoral stay at the Technical University of Munich (2020-2021), he was appointed Associate Professor in Biopharmaceutical Production Technology at Ghent University in Belgium. In 2024, he was appointed professor of Biopharmaceutical Technology at the TUM School of Life Sciences.
Awards
- ERC Starting Grant (2024)
- TUM Ambassador (2023)
- Carl Wilhelm Scheele Award from the DPhG (2020)
- Peter and Traudl Engelhorn Fellowship (2019)
- AbbVie Best Doctoral Thesis Award (2019)
Key Publications
Trommer, J., Lesniowski, F., Buchner, J. and Svilenov, H.L.* "Specific features of a scaffolding antibody light chain", Protein Science, 2024, 33, 4990.
AbstractSvilenov, H.L.*, Arosio, P., Menzen, T., Tessier, P. and Sormanni, P. "Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties", MAbs, 2023, 15, 2164459.
AbstractPasson, M., De Smedt, S., & Svilenov, H. L.* "Principles of antibodies with ultralong complementarity-determining regions and picobodies", Biotechnology Advances, 2023, 64, 108120.
AbstractSvilenov, H. L.*, Delhommel, F., Siebenmorgen, T., Rührnößl, F., Popowicz, G. M., Reiter, A., Sattler, M., Brockmeyer, C. and Buchner, J.* "Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2", Communications Biology, 2023, 6, 386.
AbstractSvilenov, H. L.*, Sacherl, J., Protzer, U., Zacharias, M., & Buchner, J.* "Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design", Nature Communications, 2021, 12, 6737.
AbstractIf you wish your profile to be changed or updated please contact Franz Langer.